What’s in a Name?
Histone Deacetylases Can Work Without Deacetylating Histones
By Anette Breindl
Wednesday, November 27, 2013
Histone deacetylases (HDACs) help control how accessible DNA is to the transcription machinery of the cell. They were the first enzymes to be targeted by drugs trying to affect cellular epigenetics, and multiple companies are in multiple clinical trials for multiple indications with drugs that hope to join FDA-approved HDAC inhibitors Istodax (romidepsin, Celgene Corp.) and Zolinza (vorinostat, Merck & Co Inc.) on the market. But scientists from the University of Pennsylvania have demonstrated that in some cases, HDACs’ effects on cells are not due to their effects on histone acetylation, but through some other mechanism.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.